Immunofluorescent localization of C-erbB-2 oncoprotein in breast cancer: A preliminary study

Human Antibodies

Volumn 11, Issue 3, 2002, Pages 73-77

  Meenakshi, A ^a   Suresh Kumar, R ^a   Siva Kumar, N ^a   Ganesh, V ^a  

^a CANCER INSTITUTE WIA   (India)

Author keywords

C erbB 2; Immunofluorescence; MAb CIBCgp185

Indexed keywords

ANTIGEN; IMMUNOGLOBULIN G2A; MONOCLONAL ANTIBODY; ONCOPROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ARTICLE; BREAST; BREAST CARCINOMA; CANCER CELL CULTURE; CELL CULTURE; CONTROLLED STUDY; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; ONCOGENE C ERB; PRIORITY JOURNAL; PROTEIN LOCALIZATION; TUMOR CELL LINE; BREAST TUMOR; CHEMISTRY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE;

BREAST NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; RECEPTOR, ERBB-2; TUMOR CELLS, CULTURED;

EID: 0036444212     PISSN: 10932607     EISSN: None     Source Type: Journal    
DOI: 10.3233/hab-2002-11303     Document Type: Article

References (21)

1. T. Akiyama, C. Sudo, M. Ogawara, K. Toyoshima and T. Yamamoto, The product of the C-erbB-2 gene: A 185-kilodalton glycoprotein with tyrosine kinase activity, Science 232 (1986), 1644-1646.
2. D.J. Slamon, G.M. Clark, S.G. Wong, W.J. Levin, A. Ull-rich and W.L. Mcguire, Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene, Science 235 (1987), 177-182.
3. M.M. Goldenburg, Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer, Clin Ther 21 (1999), 309-318.
4. M.J. van de Vijver, Assessment of the need and appropriate method for testing for the human epidermal growth factor receptor-2 (HER-2), Eu J Cancer 37 (2001), S11-S17.
5. M. Dowsett, T. Cooke, I. ElliS, W.J. Gullick, B. Gusterson, E. Mallon and R. Walker, Assessment of HER2 status in breast cancer: Why, when and how? Eur J Cancer 36 (2000), 170-176.
6. A. Meenakshi, R. Suresh Kumar and N. Siva Kumar, Generation of monoclonal antibody CIBCgp185 against C-erbB-2 oncoprotein and its clinical evaluation, Hum Antibod. 10 (2001), 101-107.
7. A. Meenakshi, R. Suresh Kuma and N. Siva Kumar, ELISA for quantitation of serum C-erbB-2 oncoprotein in breast cancer patients, J Immunoassay and Immunochemistry (2002), in press.
8. A. Meenakshi, R. Suresh Kumar, v. Ganesh and N. Siva Kumar, Preliminary study on immunoscintigraphy of experimental tumor models using Technicium-99m labelled anti-C-erbB-2 monoclonal antibody, J Tumori (2002), in press.
9. C.J. Dean, S.A. Eccles, M. Valeri, G. Box, S. Allan, C. McFar-lane, J. Sandle and J. Styles, Rat MAbs to the product of the C-erbB-2 proto-oncogene for diagnosis and therapy in breast cancer, Cell Biophysics 22 (1993), 111-127.
10. A. Piffanelli, R. Dittadi, L. Catozzi, M. Gion, G. Capitanio, M.C. Gelli, A. Brazzale, B. Malagutti, D. Pellizola, A. Menegon, G. Giovannini and G. Gardini, Determination of ErbB-2 protein in different breast cancer tissues by different methods. Relationships with other biological parameters, Breast Cancer Res Treat. 29 (1996), 3-9.
11. H. Hofler, R.A. DeLellis and H.J. Wolfe, In situ hybridization and immunohistochemistry, in: Advances in Immunohistochemistry, A.Ronald. Delellis, Raven Press, New york, 1988, pp 47-66.
12. R.L. Ridolfi, M.R. Jamehdor and J.M. Arber, HER-2/neu testing in breast carcinoma: A combined immunohistochemical and fluorescence in situ hybridization approach, Mod Pathol. 13 (2000), 866-873.
13. R.R. Tubbs, J.D. Pettay, P.C. Roche, M.H. Stoler, R.B. Jenkins and T.M. Grogen, Discrepancies in clinical laboratory testing of eligibility of trastuzumab therapy: Apparent immunohistochemical false positives do not get the message, J Clin Oncol. 19 (2001), 2714-2721.
14. T.W. Jacobs, A.M. Gown, H. Yaziji, M. Barnes and S.J. Schnitt, Specificity of herceptest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration approved scoring system. J Clin Oncol. 17 (1999), 1983-1987.
15. T.W. Jobs, A.M. Gown, H. Yaziji, M.J. Barnes and S.J. Schnitt, Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer, J Clin Oncol. 17 (1999), 1974-1982.
16. A. Lebeau, D. Deimling, C. Kaltz, A. Sendelhofert, A. Iff, B. Luthardt, M. Untch and U. Lohrs, HER-2/neu analysis in archival tissue samples of human breast cancer: Comparison of immunohistochemistry and fluorescence in situ hybridization, J Clin Oncol. 19 (2001), 354-363.
17. V. Stearns, Y. Yamuchi and D.F. Hayes, Circulating tumor markers in breast cancer: Accepted utilities and novel prospects, Breast Cancer Res Treat. 52 (1998), 239-259.
18. B.G. Brenner, S. Jothy, J. Shuster and A. Fuks, Monoclonal antibodies to human lung tumor antigens demonstrated by immunofluorescence and immunoprecipitation, Cancer Res. 42 (1982), 3187-3192.
19. H.H. Engelhard, M. Wolters and P.S. Criswell, Analysis of C-erbB-2 protein content of human glioma cells and tumor tissue, J Neurooncol. 23 (1995), 31-40.
20. J.J. Starling, R.J. Cote, P. Marder, M.J. Borowitz and D.A Johnson, Tissue distribution and cellular location of the antigens recognized by human monoclonal antibodies 16.88 and 28A32, Cancer Res. 48 (1988), 7273-7278.
21. S.N. Huang, H. Minassian and J.D. More, Application of im-munofluorescent staining on paraffin sections improved by trypsin digestion, Lab Invest. 35 (1976), 383-390.